問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Digestive System Department

Kaohsiung Veterans General Hosptial (在職)

Digestive System Department

更新時間：2023-09-19

胡琮輝
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

13Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

胡琮輝

List

62Cases

2013-06-01 - 2014-12-31

Phase III

A phase III randomised, double-blind and placebo-controlled study of BI 207127 NA in combination with faldaprevir and ribavirin for chronic genotype 1b hepatitis C virus infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferon

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BI 207127 , Faldaprevir (BI 201335 NA)

Participate Sites
10Sites

Terminated10Sites

2012-09-14 - 2016-12-31

Phase III

A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in treatment-naïve and prior relapser patients with genotype 1 chronic hepatitis C infection.

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BI 201335

Participate Sites
9Sites

Terminated9Sites

2011-09-30 - 2014-12-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-08-01 - 2014-06-30

Phase III

A phase 3 study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin(P/R), Intolerant or Ineligible to P/R Subjects and Treatment –Naïve Subjects with Chronic Hepatitis C Genotype 1b Infection

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    Asunaprevir (BMS-650032)、Daclatasvir (BMS-790052)

Participate Sites
8Sites

Terminated8Sites

2012-10-01 - 2015-04-30

Phase II

An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BMS-650032 Asunaprevir / BMS-790052 Daclatasvir

Participate Sites
8Sites

Terminated8Sites

2013-02-01 - 2016-12-31

Phase III

A Phase 3 Randomized, Double Blind, Regional Multi-National Evaluation of Daclatasvir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects with Chronic Hepatitis C Genotypes 1 and 4

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BMS-790052

Participate Sites
10Sites

Terminated10Sites

2014-07-01 - 2015-12-31

Phase III

A Phase 3 Study of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects with Chronic Hepatitis C Genotype 1 (UNITY 4)

  • Condition/Disease

    Chronic Hepatitis C Genotype 1

  • Test Drug

    Daclatasvir/Asunaprevir/BMS-791325; Film coated tablet; 30 mg/200 mg/75 mg (as the free base)

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

彭成元
China Medical University Hospital

Digestive System Department

2012-03-01 - 2014-11-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-06-01 - 2014-08-31

Phase I/II

A Phase I/II, Open-label, Randomized, Active Control, Dose Finding Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of P1101 in Interferon-Naïve Subjects with Chronic Hepatitis B Virus Infection

  • Condition/Disease

    Hepatitis B virus

  • Test Drug

    P1101

Participate Sites
9Sites

Terminated9Sites

2012-05-01 - 2013-08-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Terminated15Sites

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB